Headlands Technologies LLC Buys Shares of 49,478 Gilead Sciences, Inc. $GILD

Key Points

• Headlands Technologies acquired 49,478 Gilead Sciences shares worth approximately $6.25 million, while institutional investors collectively own 83.67% of the company.
• Gilead received key regulatory approvals for Bixlenvo, a once-daily HIV treatment, and Trodelvy plus Keytruda for certain metastatic triple-negative breast cancer patients, expanding its HIV and oncology opportunities.
• Analysts maintain a broadly positive outlook, with a “Moderate Buy” consensus and average price target of $158.04. Gilead also reported quarterly revenue above expectations and declared a $0.82 quarterly dividend, although insiders have recently sold shares under pre-arranged trading plans.

Headlands Technologies LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 49,478 shares of the biopharmaceutical company's stock, valued at approximately $6,251,000. Gilead Sciences accounts for about 0.7% of Headlands Technologies LLC's portfolio, making the stock its 27th largest position.

Several other institutional investors and hedge funds have also modified their holdings of the business. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences in the 4th quarter worth $25,000. Persistent Asset Partners Ltd purchased a new position in Gilead Sciences during the second quarter valued at $25,000. Kimelman & Baird LLC purchased a new position in Gilead Sciences during the second quarter valued at $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 85 shares during the period. Finally, Quattro Advisors LLC bought a new stake in Gilead Sciences during the fourth quarter valued at about $26,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The FDA approved Bixlenvo, a once-daily single-tablet regimen combining bictegravir and lenacapavir for virologically suppressed adults with HIV. It is the first and only single-tablet option for patients on complex regimens who cannot use currently available alternatives, potentially expanding Gilead’s HIV franchise and supporting its longer-term lenacapavir strategy. Reuters FDA approval article
• Positive Sentiment: The European Commission approved Trodelvy plus Keytruda for certain first-line metastatic triple-negative breast cancer patients, strengthening Gilead’s oncology portfolio and adding a potential growth opportunity outside its core HIV business. EU Trodelvy approval article
• Neutral Sentiment: Analysts remain broadly constructive, with a consensus “Moderate Buy” rating and an average price target of approximately $158. However, GILD’s strong multi-year advance may have raised expectations and limited the immediate upside from the Bixlenvo approval. Gilead valuation article
• Negative Sentiment: Director Anthony Welters sold 18,000 shares worth about $2.68 million, reducing his position by roughly 58%. The sale occurred under a pre-arranged Rule 10b5-1 plan, making it a limited bearish signal, but it may still weigh modestly on investor sentiment. SEC insider transaction filing

Gilead Sciences Price Performance

GILD opened at $145.68 on Monday. The company has a market capitalization of $180.64 billion, a PE ratio of -54.56 and a beta of 0.32. The firm has a 50-day simple moving average of $134.25 and a two-hundred day simple moving average of $136.51. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company's revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.01 EPS. Analysts forecast that Gilead Sciences, Inc. will post -0.5 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.3%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences's payout ratio is currently -122.85%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the sale, the chief financial officer owned 165,646 shares of the company's stock, valued at $22,918,780.56. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the transaction, the director owned 12,894 shares of the company's stock, valued at $1,916,306.28. This trade represents a 58.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 90,000 shares of company stock valued at $12,266,220 in the last three months. Corporate insiders own 0.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on GILD. HSBC raised Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Truist Financial reduced their target price on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating for the company in a report on Tuesday, July 7th. Morgan Stanley decreased their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating on the stock in a research note on Monday, July 27th. Weiss Ratings downgraded shares of Gilead Sciences from a "buy (b-)" rating to a "hold (c-)" rating in a report on Tuesday, August 11th. Finally, Wall Street Zen raised shares of Gilead Sciences from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $158.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source